At the 19th World Conference on Lung Cancer, everyone was excited when Dr. De Koning presented the astonishing results of the Dutch-Belgian Lung Cancer Screening Trial NELSON.
The NELSON study results impressively show that low dose CT screening decreases mortality by 26% in asymptomatic men at high risk for lung cancer. For women, the prospects are even better: NELSON has shown a mortality reduction between 61% at 8 years and 39% at 10 years.
Following the US National Lung Screening Trial NLST, NELSON is the second largest trial that has given strong evidence for the benefits of low dose CT lung cancer screening programs. This is a giant step towards the introduction of lung cancer screening programs in the EU saving thousands of lives.
Veolity Supports Radiologists
MeVis Medical Solutions, the market leader in mammography screening software, offers Veolity: the software solution for effective lung screening reading available today.
Veolity supports the radiologist with its computer-aided detection (CAD) of lung nodules based on artificial intelligence, automatic nodule segmentation and volume measurements, streamlined current-prior workflow, advanced reporting in addition to other smart features and technology.
Veolity is available for Europe, the U.S., Canada, Australia, New Zealand and Republic of Korea.
Veolity 1.1 supports ACR Lung_RADS and segmentation of part-solid lung nodules
Bremen/Germany, May 13, 2015 - Early detection of lung cancer helps save lives. In the U.S., leading market of medical technology, CT lung cancer screening was approved by the U.S. Centers for Medicare & Medicaid Services (CMS) in the fourth quarter of 2015. Screening programs have already been started. European countries are expected to follow.
With the newly released Veolity version 1.1, MeVis Medical Solutions AG continues to support imaging centers to handle the vast number of clients, and to implement lung cancer screening guidelines and quality requirements.
Veolity is a vendor-neutral CT image analysis software application, designed for efficient reading and reporting workflow in a high throughput environment like CT lung cancer screening. It brings together lung CAD (computer-aided detection) of solid pulmonary nodules, integration and automatic registration of prior studies, and semi-automatic nodule segmentation.
The new release Veolity 1.1 provides these major features:
"We are confident that the inclusion of the ACR Lung-RADS standard into Veolity will be of tremendous help for lung cancer screening programs. Veolity finally provides all tools and information required to properly manage the follow-up of the screening participants," says Bernd Kuemmerlen, product manager, MeVis Medical Solutions AG.
For more information about Veolity, and to arrange a demonstration or a trial installation, please visit
About MeVis Medical Solutions AG
MeVis Medical Solutions AG
28359 Bremen, Germany
Phone: +49 421 22495-301